Specialty medical injectable medication program, requirement and policy updates March 2026
Review the following tables to determine changes to our specialty medical injectable medication programs and drug policy updates for March 2026.
Review the following tables to determine changes to our specialty medical injectable medication programs and drug policy updates.
Review at Launch
The following specialty medical injectable medications have been added to Review at Launch:
| Medication Name | HCPCs Code(s) |
| Boncresa® (denosumab-mobz) Biosimilar to Prolia® |
J3490/J3590/C9399 |
Note: Medications added to Review at Launch may not yet be available in the marketplace.
Medication Sourcing for All Outpatient Providers
Effective Apr. 1, 2026, the following specialty medical injectable medication is being added to Medication Sourcing for All Outpatient Providers:
| Medication Name | HCPCs Code(s) | Specialty Pharmacy |
| Papzimeos™ (zopapogene imadenovec-drba) |
J3490/J3590/C9399Biologics, Inc. |
Biologics, Inc. |
Medication Sourcing for All Outpatient Providers
Effective Apr. 1, 2026, the following specialty medical injectable medication is being added to Medication Sourcing for All Outpatient Providers:
| Medication Name | HCPCs Code(s) | Specialty Pharmacy |
| Tyruko (natalizumab-sztn) Biosimilar to Tysabri® |
Q5134 | Accredo Health Group |
Review the UnitedHealthcare Commercial Plan Medication Sourcing List.
For questions, please contact your broker or UnitedHealthcare representative.
Share
